Shizuoka, Japan

Ryusuke Takano

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 21.0

ph-index = 2

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

3 patents (USPTO):

Title: Ryusuke Takano: Innovator in Peptide-Compound Cyclization

Introduction

Ryusuke Takano is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of drug discovery through his innovative methods for cyclizing peptide compounds. With a total of 3 patents to his name, Takano is recognized for his dedication to advancing pharmaceutical research.

Latest Patents

One of Takano's latest patents is a peptide-compound cyclization method. The objective of this invention is to provide methods for discovering drugs that are effective for tough targets, which have traditionally been challenging to identify. This invention relates to novel methods for cyclizing peptide compounds, as well as novel peptide compounds and libraries that comprise these compounds, aimed at achieving the aforementioned objective.

Career Highlights

Takano is currently employed at Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work focuses on developing innovative solutions that enhance drug discovery processes. His expertise in peptide chemistry has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Takano has collaborated with notable colleagues, including Shiori Kariyuki and Takeo Iida. These collaborations have further enriched his research and contributed to the success of his projects.

Conclusion

Ryusuke Takano's contributions to the field of peptide-compound cyclization are noteworthy. His innovative methods are paving the way for new drug discoveries, showcasing his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…